In the last 15 years, the tobacco industry has marketed electronic cigarettes (e-cigarettes) as a tool to help adults to quit cigarette smoking, while also promoting their use in children and adolescents. As expected, this led to a marked increase in e-cigarette use (also called vaping) among children and adolescents in the U.S. Although the prevalence of vaping decreased after the 2019 EVALI epidemic and stricter regulations fueled by concurrent adoption of cigarette and marijuana smoking in youths, approximately 10% of middle- and high-school students in the U.S. report vaping. A growing body of experimental and epidemiologic evidence has implicated e-cigarette use in the pathogenesis of respiratory diseases such as chronic obstructive pulmonary disease (COPD), lung cancer, interstitial lung disease, and asthma. In this narrative review, we first evaluate the types and composition of e-cigarettes and trends in e-cigarette usage and then assess findings from experimental and epidemiologic studies of e-cigarette exposure and asthma published to date. We end by discussing future directions for research in this field while emphasizing the need for prevention of and screening for e-cigarette use in youths and adults, particularly those affected with asthma.

Artificial intelligence (AI), first defined in 1955 by John McCarthy, has transformed daily life across industries through applications such as chatbots, autonomous vehicles, and navigation systems. The 2022 release of ChatGPT marked a pivotal moment, highlighting AI's rapidly expanding potential. The health care industry is increasingly embracing AI-enabled tools across oncology, pathology, and radiology to augment disease screening and clinical workflows. Ambient listening technologies support clinical documentation, reduce administrative burden, and improve patient-physician interactions. Large language models combined with natural language processing are being evaluated for generating clinical summaries managing patient portal messaging and converting freehand notes to electronic health records, while also uncovering patterns in patient data to support more personalized treatments. Forward-thinking health systems are establishing informatics departments to optimize these models. Notably, with 1 in 6 adults sourcing health information from AI, rising to nearly one-quarter among individuals younger than 30 years, there is a growing need to ensure that these technologies provide accurate and reliable information to safeguard patient safety and support appropriate clinical use. PRACTALL, a collaboration between the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy & Clinical Immunology, aims to equip allergist-immunologists with essential AI insights highlighting tools for clinical practice, education, and research. By addressing potential pitfalls and biases, PRACTALL illustrates how AI can enhance efficiency, improve patient care, and alleviate administrative burdens in health care.